• John E Anderson and John Jack L Leahy.
• Internist, Past President, The Frist Clinic, Nashville, Tennessee.
• Am. J. Med. 2025 Mar 1; 138 (3): e48e48.

AbstractType 2 diabetes is a progressive disease that often requires therapeutic intensification. Patients with type 2 diabetes frequently experience complications related to hyperglycemia, treatment-induced hypoglycemia, and comorbidities. Management of patients with type 2 diabetes is complicated and must be individualized, though guidelines from both the American Diabetes Association and the American Association of Clinical Endocrinologists/American College of Endocrinology provide treatment algorithms detailing therapeutic escalation with both oral and injectable therapies according to glycated hemoglobin (A1c) level. The development of injectable glucagon-like peptide-1 (GLP-1) receptor agonists has expanded management options and provided therapies that do not have some of the adverse events commonly associated with many other therapies used to treat type 2 diabetes. These incretin-based therapies, available in both daily and weekly formulations, have been shown to significantly reduce A1c levels, body weight, and cardiovascular risk factors. In this 4-part series, 2 expert physicians discuss clinical profiles of GLP-1 receptor agonists, strategies to reduce cardiovascular risk in type 2 diabetes, barriers to the use of injectable noninsulin therapies, and practical recommendations for noninsulin injectable therapies. These accredited educational programs are available online at https://glp1cme.elsevierresource.com/.Copyright © 2024. Published by Elsevier Inc.

26 keywords...

hide…